A van Elsas
Overview
Explore the profile of A van Elsas including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
20
Citations
1151
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Vukovic N, van Elsas A, Verbeek J, Zaiss D
Clin Exp Immunol
. 2020 Nov;
203(3):351-365.
PMID: 33155272
The clinical application of monoclonal antibodies (mAbs) has revolutionized the field of cancer therapy, as it has enabled the successful treatment of previously untreatable types of cancer. Different mechanisms play...
2.
Rullmann J, Struemper H, Defranoux N, Ramanujan S, Meeuwisse C, van Elsas A
Syst Biol (Stevenage)
. 2006 Sep;
152(4):256-62.
PMID: 16986268
A large-scale mathematical model, the Entelos Rheumatoid Arthritis (RA) PhysioLab platform, has been developed to describe the inflammatory and erosive processes in afflicted joints of people suffering from RA. The...
3.
Sutmuller R, van Duivenvoorde L, van Elsas A, Schumacher T, Wildenberg M, Allison J, et al.
J Exp Med
. 2001 Sep;
194(6):823-32.
PMID: 11560997
Therapeutic efficacy of a tumor cell-based vaccine against experimental B16 melanoma requires the disruption of either of two immunoregulatory mechanisms that control autoreactive T cell responses: the cytotoxic T lymphocyte-associated...
4.
van Elsas A, Sutmuller R, Hurwitz A, Ziskin J, Villasenor J, Medema J, et al.
J Exp Med
. 2001 Aug;
194(4):481-9.
PMID: 11514604
We have previously shown that small B16 melanomas can be successfully treated using a combination of anti-cytotoxic T lymphocyte antigen (CTLA)-4 monoclonal antibody with a granulocyte/macrophage colony-stimulating factor (GM-CSF) producing...
5.
Sullivan T, Letterio J, van Elsas A, Mamura M, van Amelsfort J, Sharpe S, et al.
Proc Natl Acad Sci U S A
. 2001 Feb;
98(5):2587-92.
PMID: 11226283
Similarities in the phenotypes of mice deficient for cytotoxic T lymphocyte antigen-4 (CTLA-4) or transforming growth factor-beta1 (TGF-beta1) and other observations have led to speculation that CTLA-4 mediates its inhibitory...
6.
Hurwitz A, Kwon E, van Elsas A
Curr Opin Immunol
. 2000 Sep;
12(5):589-96.
PMID: 11007364
Advances in our understanding of T cell costimulatory molecules have provided a vast array of novel approaches to tumor immunotherapy. In the past year, combinatorial immunotherapy based on earlier studies...
7.
van Elsas A, Hurwitz A, Allison J
J Exp Med
. 1999 Aug;
190(3):355-66.
PMID: 10430624
We examined the effectiveness of cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) blockade, alone or in combination with a granulocyte/macrophage colony-stimulating factor (GM-CSF)-expressing tumor cell vaccine, on rejection of the highly...
8.
Griffioen M, van Elsas A, Schrier P, Pustelnik T, Eichler H, Wolff K, et al.
J Invest Dermatol
. 1999 Mar;
112(3):332-6.
PMID: 10084311
Overexpression of the proto-oncogene c-myc has been associated with neoplastic transformation in a variety of tumors. For human melanoma high c-myc expression has been found in the vertical growth phase...
9.
Zerp S, van Elsas A, Peltenburg L, Schrier P
Br J Cancer
. 1999 Mar;
79(5-6):921-6.
PMID: 10070891
In melanoma, the relationship between sun exposure and the origin of mutations in either the N-ras oncogene or the p53 tumour-suppressor gene is not as clear as in other types...
10.
Jansen B, Brown B, Bryan R, van Elsas A, Muller M, Wolff K, et al.
Nat Med
. 1998 Feb;
4(2):232-4.
PMID: 9461199
Malignant melanoma is a prime example of cancers that respond poorly to various treatment modalities including chemotherapy. A number of chemotherapeutic agents have been shown recently to act by inducing...